Kalaris Therapeutics Inc
NASDAQ:KLRS · NASDAQ Global Market
-$0.03 today
Vol 0.05M · Avg 0.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:KLRS · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$44.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.15, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $13.0K | $0 | $0 | $0 -100.0% | $1.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$13.0K | $0 | $0 | $0 +100.0% | -$1.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $30.8M +149.2% | $12.3M +5.4% | $11.7M -0.5% | $11.8M -90.2% | $119.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $15.4M -64.1% | $42.9M +2342.6% | $1.8M -21.7% | $2.2M -95.4% | $49.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $46.1M -16.5% | $55.3M +310.4% | $13.5M -3.9% | $14.0M -91.7% | $168.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $13.0K | $0 | $0 | $0 -100.0% | $1.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$42.0M +28.6% | -$58.8M -319.4% | -$14.0M +8.1% | -$15.3M +91.0% | -$169.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$46.2M +16.5% | -$55.3M -310.4% | -$13.5M +3.9% | -$14.0M +91.8% | -$169.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $5.5M | $0 | $0 -100.0% | $1.3M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.4M | $0 -100.0% | $687.0K +192.3% | $235.0K | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.7M +177.3% | -$3.5M -184.5% | -$1.2M +16.5% | -$1.5M -30.1% | -$1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$43.4M +26.1% | -$58.8M -299.8% | -$14.7M +5.1% | -$15.5M +90.9% | -$171.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 -100.0% | $1.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$43.4M +26.1% | -$58.8M -299.8% | -$14.7M +5.1% | -$15.5M +91.0% | -$172.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +75.7% | -$12 +72.1% | -$42 +16.9% | -$51 +19.6% | -$63 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +75.7% | -$12 +72.1% | -$42 +16.9% | -$51 +19.6% | -$63 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $15.3M +204.8% | $5.0M +10.7% | $4.5M +35.7% | $3.3M +22.1% | $2.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $15.3M +204.8% | $5.0M +10.7% | $4.5M +35.7% | $3.3M +22.1% | $2.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Metagenomi, Inc. Common Stock
MGX
$45.18M
Quince Therapeutics, Inc.
QNCX
$5.20M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does KLRS generate?
Kalaris Therapeutics Inc (KLRS) reported $0.00 of revenue in fiscal 2025.
Is KLRS profitable?
Kalaris Therapeutics Inc (KLRS) reported -$43,438,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.